密固达预防全髋关节置换术后并发症的临床研究

Clinical study on the prevention of complications after total hip replacement by Aclasta

目的探讨密固达预防全髋关节置换术后并发症的临床效果。方法 80例行人工髋关节置换术患者,随机分为试验组和对照组,各40例。对照组采取常规术后治疗,试验组在对照组基础上使用密固达治疗,比较两组患者术后并发症发生情况和髋关节Harris评分。结果试验组并发症发生率为2.5%,明显低于对照组的15.0%,差异有统计学意义(P<0.05);试验组髋关节Harris评分为(87.1±4.3)分优于对照组的(84.1±5.7)分,差异有统计学意义(P<0.05)。结论对全髋关节置换术后患者采取密固达治疗,可以明显降低并发症的发生,提高患者术后生活水平,值得在临床推广。

Objective To investigate the clinical effect on the prevention of complications after total hip replacement by Aclasta. Methods A total of 80 patients with artificial hip replacement were randomly divided into the experimental group and the control group, 40 cases in each group. The control group was given routine postoperative treatment, the experimental group was given Aclasta for treatment on the basis of control group. The postoperative complications and Harris score of hip joint between the two grousp were compared. Results The incidence of complications in the experimental group was 2.5%, which was significantly lower than 15.0% in the control group, the difference was statistically significant（P〈0.05）. The Harris score of hip joint in the experimental group was（87.1±4.3） scores, which was significantly better than（84.1±5.7） scores of the control group, the difference was statistically significant（P〈0.05）. Conclusion The application of Aclasta therapy in patients after total hip replacement can significantly reduce the incidence of complications and improve the postoperative living standard of patients, which is worthy of clinical promotion.